These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 21135689)

  • 1. Use of lanreotide for the treatment of gastrointestinal fistulae.
    Clive K; Hardin M; White C; Larson C; Oh J; Cohn S
    Ann Surg; 2011 Jan; 253(1):211; author reply 211-2. PubMed ID: 21135689
    [No Abstract]   [Full Text] [Related]  

  • 2. [Lanreotide++: a new therapeutic option in acromegaly].
    Díez JJ
    Med Clin (Barc); 1996 Sep; 107(7):257-69. PubMed ID: 8975096
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful treatment of an advanced hepatocellular carcinoma with the long-acting somatostatin analog lanreotide.
    Raderer M; Hejna MH; Kurtaran A; Kornek GV; Valencak JB; Oberhuber G; Vorbeck F; Virgolini I; Scheithauer W
    Am J Gastroenterol; 1999 Jan; 94(1):278-9. PubMed ID: 9934776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New drugs: Maraviroc and Lanreotide.
    Hussar DA
    J Am Pharm Assoc (2003); 2007; 47(6):778-83. PubMed ID: 18032144
    [No Abstract]   [Full Text] [Related]  

  • 5. [Partial regression of a desmoid tumor after prolonged treatment with lanreotide].
    Mannant PR; Beau P; De Lédinghen V; Barrioz T; Genestin E
    Gastroenterol Clin Biol; 1995 Dec; 19(12):1072-3. PubMed ID: 8729428
    [No Abstract]   [Full Text] [Related]  

  • 6. [Peritoneal mesothelioma: long survival with intraperitoneal chemotherapy, lanreotide and mucolytics].
    Montmayeur G; Thivat E; Gimbergues P; Dib M; Leheurteur M; Curé H; Chollet P; Durando X
    Gastroenterol Clin Biol; 2008 Oct; 32(10):874-5. PubMed ID: 18353584
    [No Abstract]   [Full Text] [Related]  

  • 7. Randomized, placebo-controlled, double-blind study of the efficacy of lanreotide 30 mg PR in the treatment of pancreatic and enterocutaneous fistulae.
    Gayral F; Campion JP; Regimbeau JM; Blumberg J; Maisonobe P; Topart P; Wind P;
    Ann Surg; 2009 Dec; 250(6):872-7. PubMed ID: 19953707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comment of long-acting lanreotide inducing clinical and biochemical remission of acromegaly caused by disseminated GHRH secreting carcinoid.
    Krassowski J; Zgliczyński W; Jeske W; Zgliczyński S
    J Clin Endocrinol Metab; 1999 May; 84(5):1761-2. PubMed ID: 10323416
    [No Abstract]   [Full Text] [Related]  

  • 9. Slow-release lanreotide treatment in endocrine gastrointestinal tumors.
    Tomassetti P; Migliori M; Gullo L
    Am J Gastroenterol; 1998 Sep; 93(9):1468-71. PubMed ID: 9732927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin analogs in acromegaly.
    Freda PU
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3013-8. PubMed ID: 12107192
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results.
    Raderer M; Hamilton G; Kurtaran A; Valencak J; Haberl I; Hoffmann O; Kornek GV; Vorbeck F; Hejna MH; Virgolini I; Scheithauer W
    Br J Cancer; 1999 Feb; 79(3-4):535-7. PubMed ID: 10027326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of lanreotide on prolactin level in patients with pituitary mixed tumors].
    Wasko R; Sawicka J; Stachowiak C; Kozak W; Junik R; Sowinski J
    Ann Endocrinol (Paris); 2002 Dec; 63(6 Pt 1):532-5. PubMed ID: 12527855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interim Results on the Influence of Lanreotide on Uptake of [68Ga]-DOTATATE in Patients With Metastatic or Unresectable NET: No Evidence for Discontinuation of Lanreotide Before [68Ga]-DOTATATE PET/CT.
    Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 7):13-5. PubMed ID: 27168107
    [No Abstract]   [Full Text] [Related]  

  • 14. Lanreotide for the treatment of acromegaly.
    Castinetti F; Saveanu A; Morange I; Brue T
    Adv Ther; 2009 Jun; 26(6):600-12. PubMed ID: 19533047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lanreotide in the treatment of the dumping syndrome].
    Alcalde Rubio M; Carro Rosell J; Morales Pérez F
    Rev Esp Enferm Dig; 1999 Mar; 91(3):223-4. PubMed ID: 10231313
    [No Abstract]   [Full Text] [Related]  

  • 16. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide.
    Karavitaki N; Turner HE; Adams CB; Cudlip S; Byrne JV; Fazal-Sanderson V; Rowlers S; Trainer PJ; Wass JA
    Clin Endocrinol (Oxf); 2008 Jun; 68(6):970-5. PubMed ID: 18031313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors.
    Ducreux M; Ruszniewski P; Chayvialle JA; Blumberg J; Cloarec D; Michel H; Raymond JM; Dupas JL; Gouerou H; Jian R; Genestin E; Hammel P; Rougier P
    Am J Gastroenterol; 2000 Nov; 95(11):3276-81. PubMed ID: 11095353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of prolonged-release somatostatin analog monotherapy in metastatic endocrine tumors].
    Kanyinda-K JM; Samalin E; Sebah H; Gallix B; Ychou M
    Gastroenterol Clin Biol; 2008 Dec; 32(12):989-91. PubMed ID: 18945567
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of type II gastric carcinoid tumors with somatostatin analogues.
    Tomassetti P; Migliori M; Caletti GC; Fusaroli P; Corinaldesi R; Gullo L
    N Engl J Med; 2000 Aug; 343(8):551-4. PubMed ID: 10954763
    [No Abstract]   [Full Text] [Related]  

  • 20. A dose-finding study of lanreotide (a somatostatin analog) in patients with colorectal carcinoma.
    Di Leo A; Bajetta E; Ferrari L; Biganzoli L; Mariani L; Carnaghi C; Camerini E; Buzzoni R; Ruiz JM
    Cancer; 1996 Jul; 78(1):35-42. PubMed ID: 8646723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.